Clinical Study Of Xiao’ai Jiedu Ⅲ Prescription Combined With Chemotherapy On Advanced Gastric Adenocarinoma Of The Heat And Yin-deficiency Syndrome

Objective:The understanding of modern medicine and traditional Chinese medicine(TCM)for gastric cancer were reviewed systematically,then combined with TCM theory of cancer pathogenesis and the research progress of Xiao’ai Jiedu Prescription,Under the guidance of the both theory,through observe study of the efficacy and safety of Xiao’ai Jiedu Ⅲ Prescription combined with chemotherapy on advanced gastric adenocarinoma of the Heat and Yin-deficiency Syndrome to explore the theoretical basis of Xiao’ai Jiedu method for the treatment of gastric cancer,in order to verity the scientific nature of the clinical experience of famous traditional Chineses medicine and the theoretical system of syndrome differentiation and treatment of TCM,inhert and develop the experience of famous traditional Chinese Medicine,to provide a clinical basis for the research and development of new dugs and multidisciplinary treatment of gastric cancer.Methods:Respectively collected 30 cases of advanced gastric cancer and stomach yin deficiency type patients as treatment group(chemotherapy+Xiao’ai Jiedu Ⅲ Prescription)and control group(simple chemotherapy)in the Xuzhou Central Hospital and Wuxi City Hospital of traditional Chinese medicine.Respectively record the tumor size,tumor markers value,TCM syndrome score,KPS score,liver and kidney function of the two groups in the observation scale before treatment and after 4 cycles,use SPSS 19.0 statistical software to analyze the results of the two groups,compared the recent efficacy and safety of the two groups.Results:Before treatment,there was no significant difference(P>0.05)between the two groups in age(P=0.604>0.05),gender(P=0.302>0.05),initial treatment and retreatment(P=0.197>0.05),surgery or not(P=0.602>0.05),stage(P=0.748>0.05).tissue differentiation degree(P=0.884>0.05),lesion location(P=0.871>0.05),chemotherapy regimen(P=0.678>0.05)and the other basic information,so the patients in the two groups were comparable.After treatment,the objective curative effect evaluation of the tumor(P=0.303>0.05),tumor markers(CEA:0.186>0.05;CA199:P=0.779>0.05;CA724:P=0.085>0.05;CA50:P=0.53>0.05),liver function(AST:P=0.333>0.05;ALT:P=0.709>0.05),renal function(Cr:P=1>0.05;BUN:P=1>0.05)of the two groups showed no significant difference(P>0.05),was not statistically significant,which is suggesting that Xiao’ai Jiedu Ⅲ Prescription can not effectively reduce the size of tumor,can not reduce the tumor marker,does not increase the toxicity of kidney and liver;However,in TCM symptom score(P=0.023<0.05),KPS score of QOL(P=0.042<0.05),WBC(P=0.046<0.05),HB(P = 0.013<0.05),PLT(P=0.024<0.05),nausea and vomiting(P=0.019<0.05)have significant differences in the comparison(P<0.05),with statistical significance,suggesting that Xiao’ai Jiedu Ⅲ Prescription can effectively improve TCM clinical symptom of patients,especially in the stomachache(P=0.025<0.05),eat less(P=0.026<0.05),fatigued and weak(P=0.013<0.05)has the advantages(P<0.05),while in the gastrectasia(P=0.398>0.05),pantothenic acid(P=0.426>0.05),eating obstruction(P=0.332>0.05),belching(P=0.787>0.05),emaciation(P=0.336>0.05),the treatment group had no obvious advantage(P>0.05).Conclusions:Compared to chemotherapy alone,Xiao’ ai Jiedu Ⅲ Prescription combined with chemotherapy has a certain effect on increasing curative effect and reducing toxicity in the treatment of patients with advanced gastric adenocarinoma of the Heat and Yin-deficiency Syndrome,has an advantage in improving TCM syndrome and QOL,reducing side effects.However,there is no obvious advantage in reducing the size of the tumor and the tumor markers,and the safety is good,the liver and kidney toxicity is not increased obviously,and the patients were well tolerated.